Table 1.
Baseline characteristics of patients included in 18-month follow-up
| Alteplase group (n=1169) | Control group (n=1179) | ||
|---|---|---|---|
| Region | |||
| Americas (Canada, Mexico) | 5 (<1%) | 6 (1%) | |
| Australia | 89 (8%) | 90 (8%) | |
| Eastern Europe (Poland) | 158 (14%) | 159 (13%) | |
| Northwest Europe (UK, Austria, Belgium) | 550 (47%) | 556 (47%) | |
| Scandinavia (Norway, Sweden) | 251 (21%) | 250 (21%) | |
| Southern Europe (Italy) | 116 (10%) | 118 (10%) | |
| Age | |||
| 18–50 years | 49 (4%) | 57 (5%) | |
| 51–60 years | 83 (7%) | 81 (7%) | |
| 61–70 years | 153 (13%) | 158 (13%) | |
| 71–80 years | 291 (25%) | 304 (26%) | |
| 81–90 years | 523 (45%) | 512 (43%) | |
| >90 years | 70 (6%) | 67 (6%) | |
| Women | 592 (51%) | 596 (51%) | |
| National Institutes of Health stroke scale score | |||
| 0–5 | 235 (20%) | 236 (20%) | |
| 6–10 | 323 (28%) | 330 (28%) | |
| 11–15 | 244 (21%) | 235 (20%) | |
| 16–20 | 207 (18%) | 219 (19%) | |
| >20 | 160 (14%) | 159 (13%) | |
| Delay in enrolment | |||
| ≤3·0 h | 320 (27%) | 307 (26%) | |
| >3·0–4·5 h | 471 (40%) | 481 (41%) | |
| >4·5–6·0 h | 378 (32%) | 389 (33%) | |
| >6·0 h | 0 (0%) | 2 (<1%) | |
| Atrial fibrillation | 347 (30%) | 331 (28%) | |
| Systolic blood pressure | |||
| ≤143 mm Hg | 380 (33%) | 380 (32%) | |
| 144–164 mm Hg | 379 (32%) | 405 (34%) | |
| ≥165 mm Hg | 410 (35%) | 394 (33%) | |
| Diastolic blood pressure | |||
| ≤74 mm Hg | 342 (29%) | 343 (29%) | |
| 75–89 mm Hg | 409 (35%) | 448 (38%) | |
| ≥90 mm Hg | 406 (35%) | 381 (32%) | |
| Blood glucose concentration* | |||
| ≤5 mmol/L | 202 (20%) | 207 (20%) | |
| 6–7 mmol/L | 501 (49%) | 485 (47%) | |
| ≥8 mmol/L | 324 (32%) | 347 (33%) | |
| Treatment with antiplatelet drugs in previous 48 h | 599 (51%) | 610 (52%) | |
| Assessment of acute ischaemic change | |||
| Scan normal | 99 (8%) | 102 (9%) | |
| Scan not normal but no sign of acute change | 551 (47%) | 579 (49%) | |
| Signs of acute change | 511 (44%) | 490 (42%) | |
| Predicted probability of poor outcome at 6 months† | |||
| <40% | 633 (54%) | 640 (54%) | |
| ≥40–<50% | 130 (11%) | 113 (10%) | |
| ≥50–<75% | 275 (24%) | 304 (26%) | |
| ≥75% | 131 (11%) | 122 (10%) | |
| Stroke syndrome | |||
| TACI | 491 (42%) | 509 (43%) | |
| PACI | 460 (39%) | 430 (36%) | |
| LACI | 137 (12%) | 133 (11%) | |
| POCI | 79 (7%) | 104 (9%) | |
| Other | 2 (<1%) | 3 (<1%) | |
Data are n (%). TACI=total anterior circulation infarct. PACI=partial anterior circulation infarct. LACI=lacunar infarct. POCI=posterior circulation infarct.
*
Baseline glucose concentration was not recorded for the first 282 patients recruited; thus, glucose measurements were available for 2066 of 2348 participants (88%; 1027 allocated to alteplase and 1039 allocated to control).
†
Calculated from a model based on age and baseline National Institutes of Health stroke scale score.22